They are extremely pleased at the extremities company called SBi…Michael P. Simpson, a former division President at Orthofix, Inc., is the new president and CEO of Small Bone Innovations, Inc. (SBi). This move will allow Anthony G. Viscogliosi, SBi’s founder, chairman and CEO since 2005, to assume the new position of Executive Chairman.
Michael P. Simpson Takes Helm at SBi
1 min read Premium comments
In the February 22, 2012 news release, Anthony Viscogliosi said, “SBi’s revenues, excluding discontinued products, have been growing at a compound average annual growth rate of 27 percent during the period 2006-2011, establishing a platform for continuing growth and profitability. SBi’s Board decided that we had reached the point where we needed a leader seasoned in growing a critical mass business into larger scale company. Michael P. Simpson is a great choice to seize this opportunity, based on his track record at Orthofix. He is an experienced professional in the orthopedics industry who understands the extremities market and the demand for evidence-based medicine in terms of pain elimination and joint preservation.”
During Simpson’s career as a division president at Orthofix, an orthopedic devices company with $575 million-plus revenues in 2011, he managed the global development and distribution internationally of the product portfolio, including foot and ankle technologies, with full P&L responsibility. Mr. Simpson will report to the Executive Chairman and the SBi Board and be a member of SBi’s Operating and Executive Committees.
As for what career experience has best prepared him for this new role, Simpson commented to OTW,
Having executive leadership roles working for an internal and external foot and ankle company, along with managing both a direct and distributor sales force has given me the experience to lead this organization to reach its full potential. Overall, I have experience managing and leading every operational function in a medical device manufacturing company.
When asked what he will tackle first, Simpson told OTW,
In short order, calibrate the operational strategy for sales distribution, product development, product marketing and operations. Additionally, take full advantage of SBI’s superior product portfolio in both upper and lower extremity.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.